J&J Seeks FDA Nod for Subcutaneous Tremfya as Induction Regimen in UC
Johnson & Johnson seeks FDA approval for subcutaneous induction regimen of Tremfya in ulcerative colitis. The move aims to provide a more convenient treatment option for patients. The drug is already approved for other indications and may help offset potential sales decline of Stelara in the IBD space.